Yes... you have a much greater chance of getting Myocarditis from Covid-19 than the vaccine. Myocarditis is more common after covid-19 infection than vaccination https://www.newscientist.com/articl...on-after-covid-19-infection-than-vaccination/ HEART inflammation triggered by some covid-19 vaccines has been a concern, especially in younger people, but a preliminary study suggests that in those most affected, it is six times more likely to occur after a coronavirus infection than after vaccination. In the past few months, some cases of this condition, known as myocarditis, have been recorded following the use of the Pfizer/BioNTech and Moderna vaccines. This has prompted concern particularly in the US and Israel, as these two countries have led the way in vaccinating younger people. The reaction happens most often in men and boys aged under 30 after their second dose, and is usually seen within 10 days, says Alma Iacob at Imperial College London. But many health bodies around the world say the benefits of vaccination still outweigh the risks for most people. Now a study in the US has analysed how often myocarditis occurs following infection with the coronavirus. Researchers analysed the records of healthcare organisations that cover a fifth of the US population. They found that, during the first 12 months of the pandemic, males aged 12 to 17 were most likely to develop myocarditis within three months of catching covid-19, at a rate of about 450 cases per million infections. This compares with 67 cases of myocarditis per million males of the same age following their second dose of a Pfizer/BioNTech or Moderna vaccine, according to figures from the US Advisory Committee on Immunization Practices. Researchers added together cases after first and second doses to reach a total rate of 77 cases per million in this male age group triggered by vaccination, a sixth that seen after infection. “If you’re focused on heart inflammation, the safer bet is to take the vaccine,” says Mendel Singer at Case Western Reserve University in Ohio, who helped carry out the study. Signs of myocarditis include chest pain, breathlessness and palpitations. Symptoms range from so mild that they go unnoticed to severe, involving permanent heart damage or death. However, extreme forms are rare and no fatalities have been reported after vaccination in the US. The causes of myocarditis are unclear. One idea is that it occurs when the immune system attacks the heart, but this hasn’t been proven. Neither is it known why it happens most often in younger males. Mild cases are usually treated with over-the-counter anti-inflammatory drugs such as ibuprofen and most people recover within a few months, says Iacob. Other triggers of the condition include flu and the flu vaccine, some medications and some illegal drugs. The small risk of myocarditis after the Pfizer/BioNTech vaccine is one reason why the UK’s Joint Committee on Vaccination and Immunisation (JCVI) hasn’t yet recommended this vaccine – the only one licensed for use in under-18s in the UK – for most children aged 12 and over. While countries such as Ireland and the US are letting teenagers get vaccinated, the JCVI said in July that only younger people who are highly vulnerable or living with someone with a weak immune system could have the jab. Iacob says people who have been vaccinated or had covid-19 should be aware of possible symptoms of myocarditis, especially chest pain that is burning or sharp and worsens on changing position. Read more: https://www.newscientist.com/articl...-19-infection-than-vaccination/#ixzz72dCPM1RM
Let's take a look at a large scale study of myocarditis and Covid vaccinations. In summary, myocarditis is rare as a side effect. Nearly all the cases are mild and fully recover within days. Young people recover quickly from rare myocarditis side effect of COVID-19 vaccine: study https://medicalxpress.com/news/2021-12-young-people-recover-quickly-rare.html
This is common and I debated about such with others here at ET a few months ago. As stated, I had Myocarditis twice as a teenager when I was rowing (on the crew team) and the team Doctors stated it was so common...it was something they looked for in members on the rowing team that had been vaccinated for anything (e.g. FLU vaccine). In fact, they said it was common in young athletes that are tall, very athletic and growing fast. It was almost as common as heart murmurs. Both times I had it Myocarditis...I also had a heart murmur. both Myocarditis and heart murmurs are so mild...many tall athletes do not know they have it. The team nutritionist changed my diet and Myocarditis cleared up on its own in less than one month... Essentially less fat in my diet and more protein, Omega-3, fiber, CoQ10, Magnesium, and L-Carnitine. Essentially a diet to help strengthen the heart muscle. I learned to make a good shake mixture out of it although my parents stated that it tasted metallic and felt slimy. In college, I knew some guys in other sports (e.g. swimming, volleyball, track n field) that were doping...a lot of those guys talked about having Myocarditis but it cleared up on its own for them too. wrbtrader
COVID Increases the Risk of Heart Failure by 72% in Unvaccinated People, Even in Mild Cases Researchers warn that countries will likely see a rise in cardiovascular problems in their populations https://people.com/health/covid-inc...ms-in-unvaccinated-people-even-in-mild-cases/ COVID-19 illness, even mild cases, can leave people with a significantly higher risk of life-threatening heart problems, a new study found. In one of the largest analyses yet of the long-term effects of COVID-19, researchers found that the virus drastically increases the chance of heart issues like failures, strokes and irregularities, and the potential of deadly blood clots in the legs and lungs for at least a year after infection. The risk of heart failure went up by 72%, heart attacks by 63% and stroke by 52%, even for people who had mild cases. The researchers, led by Dr. Ziyad Al-Aly, a clinical epidemiologist at Washington University in St. Louis, collected data for up to a year from 153,760 COVID-19 patients before vaccines were available. They compared the patients' cardiovascular health and any heart problems to two control groups — one from the same time period of more than 5.6 million people who did not contract COVID-19, and the other of 5.8 million veterans from before the pandemic. he patients had received medical care through the Department of Veterans Affairs, making them mostly white men, but even after accounting for age and race, the high risks still held. "It was a bit of a moment for us when we realized it was evident in all of these subgroups, including younger adults, older adults, Black people, white people, people with obesity and those without," Al-Aly told NBC News. "The risk was everywhere." Heart experts told the outlet that the COVID-19 vaccines, which protect against infection, likely reduce this risk. The study, published in the journal Nature Medicine last week, is also in line with previous studies about how COVID-19 affects the heart. In a Twitter thread, Al-Aly said that their research is a warning that countries will start to see a rise in cardiovascular problems in their populations. "Governments and health systems around the world should be prepared to deal with the likely significant contribution of the COVID-19 pandemic to a rise in the burden of cardiovascular diseases," he said. "Because of the chronic nature of these conditions, they will likely have long-lasting consequences for patients and health systems and also have broad implications on economic productivity and life expectancy." "Addressing the challenges posed by Long COVID will require a much needed, but so far lacking, urgent and coordinated long-term global response strategy."
Myocarditis risk significantly higher after COVID-19 infection vs. after a COVID-19 vaccine https://medicalxpress.com/news/2022-08-myocarditis-significantly-higher-covid-infection.html In a detailed analysis of nearly 43 million people, ages 13 and older, who received at least one dose of a COVID-19 vaccine in England, the risk of myocarditis in unvaccinated individuals after COVID-19 infection was at least 11 times higher compared to people who developed myocarditis after receiving a COVID-19 vaccine or booster dose between December 1, 2020 and December 15, 2021, according to new research published today in the American Heart Association's flagship, peer-reviewed journal Circulation. Several previous studies and reports from public health agencies around the world including the U.S. Centers for Disease Control and Prevention have highlighted a possible connection and potentially increased risk of myocarditis after receiving an mRNA COVID-19 vaccine, generating considerable scientific, policy and public interest . Typically trigged by a viral infection, myocarditis is the inflammation of the middle layer of the wall of the heart muscle, the myocardium. This condition is uncommon and may temporarily or permanently weaken the heart muscle and the heart's electrical system, which keeps the heart pumping normally. An episode of myocarditis may resolve on its own or with treatment, and may result in lasting damage to the heart. In the general population not during a global pandemic, it is estimated that approximately 10 to 20 people per 100,000 are diagnosed with myocarditis each year, according to the American Heart Association's 2021 scientific statement on myocarditis. "We found that across this large dataset, the entire COVID-19-vaccinated population of England during an important 12-month period of the pandemic when the COVID-19 vaccines first became available, the risk of myocarditis following COVID-19 vaccination was quite small compared to the risk of myocarditis after COVID-19 infection," says first author of the study Martina Patone, Ph.D., a statistician at the Nuffield Department of Primary Health Care Sciences at the University of Oxford in Oxford, England. "This analysis provides important information that may help guide public health vaccine campaigns, particularly since COVID-19 vaccination has expanded in many parts of the world to include children as young as 6 months old." In this study, Patone and colleagues evaluated England's National Immunization database of COVID-19 vaccinations for all people ages 13 or older who had received at least one dose of the ChAdOx1 (a two-dose adenovirus-vector COVID-19 vaccine developed by the University of Oxford and AstraZeneca, most similar to the one-dose Johnson & Johnson/Janssen COVID-19 vaccine available in the U.S.), the Pfizer-BioNTech or the Moderna COVID-19 vaccine (the same mRNA vaccines available in the U.S.) between December 1, 2020 and December 15, 2021. This dataset totaled nearly 43 million people, which included more than 21 million who had received a booster dose of any of the COVID-19 vaccines (meaning they had received a total of 3 doses of a COVID-19 vaccine). The database detailed the type of COVID-19 vaccines received, dates received and dose sequencing, along with individual demographic information including age and sex for each individual. Nearly 6 million people tested positive for COVID-19 infection either before or after COVID-19 vaccination during the study period. England's National Immunization database records were then cross-referenced and matched to the national offices with data on COVID-19 infection, hospital admission and death certificates for the same time period, December 1, 2020 through December 15, 2021. Individuals were classified based on age and sex to reveal which groups had the highest risk of myocarditis after a COVID-19 vaccine or after COVID-19 infection and hospitalization. The authors used the self-controlled case series (SCCS) method, which was developed to estimate the relative incidence of an acute event in a pre-defined post-vaccination risk period (1-28 days), compared to other times (pre-vaccination or long after vaccination). Being a within-person comparison, the analyses were controlled to adjust for any fixed characteristics, including sex, race or ethnicity, or chronic health conditions. In the overall dataset of nearly 43 million people, the analyses found: Fewer than 3,000 (n=2,861), or 0.007%, people were hospitalized or died with myocarditis during the one-year study period. 617 of these cases of myocarditis occurred during days 1-28 after receiving a COVID-19 vaccination, of which 514 were hospitalized. People who were infected with COVID-19 before receiving any doses of the COVID-19 vaccines were 11 times more at risk for developing myocarditis during days 1-28 after a COVID-19 positive test. The risk of COVID-19 infection-related myocarditis risk was cut in half among people infected after vaccination (received at least one dose of a COVID-19 vaccine). The risk of myocarditis increased after a first dose of the ChAdOx1 COVID-19 vaccine (an adenovirus-vector vaccine most similar to the Johnson & Johnson/Janssen COVID-19 vaccine available in the U.S.) and after a first, second and booster dose of any of the mRNA COVID-19 vaccines. However, the risk of vaccine-associated myocarditis was lower compared to the risk of COVID-19 infection-associated myocarditis, except for after a second dose of the Moderna vaccine. Myocarditis risk was found to be higher during days 1-28 after a second dose of the Moderna COVID-19 vaccine for people of all genders and ages, and the risk also persisted after a booster dose of the Moderna vaccine. However, people receiving a booster dose of Moderna were, on average, younger in comparison to those who received a booster dose of the ChAdOx1 or Pfizer-BioNTech vaccine, therefore, results may not be generalizable to all adults. Risk of COVID-19 vaccine-associated myocarditis among women: Of the nearly 21 million women, 7.2 million (34%) were younger than age 40, and a slightly increased risk of myocarditis was found among this younger age group after receiving a second dose of the Moderna COVID-19 vaccine: 7 estimated extra cases of myocarditis for every one million women vaccinated. Among women older than age 40, a slight increased risk of myocarditis was associated with receiving a first or third dose of the Pfizer-BioNTech COVID-19 vaccine, respectively 3 and 2 estimated additional cases of myocarditis for every one million women vaccinated. Risk of COVID-19 infection-associated myocarditis among women: Among women younger than age 40, the risk of infection-associated myocarditis was higher compared to the risk of vaccine-associated myocarditis: 8 extra cases associated with having COVID-19 infection before vaccination. Among women older than age 40, the risk of infection-associated myocarditis was higher compared to the risk of vaccine-associated myocarditis: 51 extra cases associated with having COVID-19 infection before vaccination. Risk of COVID-19 vaccine-associated myocarditis among men: Among the 18 million men in the dataset, all of whom received at least one COVID-19 vaccine, more than 6 million men (34%) were younger than age 40. An increased risk of vaccine-associated myocarditis was found in men ages 40 and younger after a first dose of either of the mRNA COVID-19 vaccines (4 and 14 estimated extra cases for every one million men vaccinated with respectively Pfizer or Moderna vaccine), or a second dose of any of the three COVID-19 vaccines available in England during the study period: 14, 11 and 97 estimated additional cases of myocarditis for every one million men vaccinated, respectively for the ChAdOx1, the Pfizer-BioNTech or the Moderna vaccine. The increased risk of developing myocarditis among males younger than age 40 was also higher after receiving two doses of the Moderna vaccine when compared to the risk of myocarditis after COVID-19 infection. The researchers noted, however, the average age of people who received the Moderna vaccine was 32 years, compared to the majority of those who received the other vaccines were older than age 40. In men ages 40 and older, a slightly increased risk of myocarditis was found after a booster dose of either of the two mRNA vaccines (Pfizer-BioNTech or Moderna): 3 estimated extra cases of myocarditis for every one million men vaccinated with either mRNA vaccine. Risk of COVID-19 infection-associated myocarditis among men: Among men younger than age 40, the risk of infection-associated myocarditis was higher compared to the risk of vaccine-associated myocarditis: 16 extra cases associated with having infection before vaccination, with the only exception of a second dose of Moderna vaccine. Among men older than age 40, the risk of infection-associated myocarditis was higher compared to the risk of vaccine-associated myocarditis: 85 extra cases associated with having infection before vaccination. "It is important for the public to understand that myocarditis is rare, and the risk of developing myocarditis after a COVID-19 vaccine is also rare. This risk should be balanced against the benefits of the COVID-19 vaccines in preventing severe COVID-19 infection. It is also crucial to understand who is at a higher risk for myocarditis and which vaccine type is associated with increased myocarditis risk, " said Professor Nicholas Mills, Ph.D., the Butler British Heart Foundation Chair of Cardiology at the University of Edinburgh and a co-author of the paper. "These findings are valuable to help inform recommendations on the type of COVID-19 vaccines available for younger people and may also help shape public health policy and strategy for COVID-19 vaccine boosters. The SARS-CoV-2 virus continues to shift, and more contagious variants arise; our hope is that this data may enable a more well-informed discussion on the risk of vaccine-associated myocarditis when considered in contrast to the net benefits of COVID-19 vaccination," said another co-author Julia Hippisley-Cox, F.R.C.P., professor of clinical epidemiology and general practice at the University of Oxford. Authors noted there are two unanswered questions that likely require further investigation. The first is about myocarditis risk among children ages 13-17 because there were too few cases of myocarditis to quantify the risk specific to this age group. Secondly, researchers were not able to directly compare the death rate after COVID-19 infection vs. death after COVID-19 vaccination since the database only included people who had received at least one COVID-19 vaccine. More expansive data and a different analysis are still needed to address these questions and numerous other COVID-19 topics. The study has two notable limitations. The number of cases of myocarditis among individuals who received a booster dose of the ChAdOx1 or Moderna vaccines was too small to calculate the risk of myocarditis. Additionally, researchers cannot exclude the possibility of over- or under-estimated risk due to misclassification of any health information in the database, though the U.K.'s National Health Service is known to provide timely and accurate data. Additional co-authors are Xue W. Mei, Ph.D.; Lahiru Handunnetthi, Ph.D.; Sharon Dixon, M.R.G.C.P.; Francesco Zaccardi, Ph.D.; Manu Shankar-Hari, Ph.D.; Peter Watkinson, M.D.; Kamlesh Khunti, F.R.G.C.P.; Anthony Harden, Ph.D.; Carol A.C. Coupland, Ph.D.; Keith M. Channon, M.D., F.R.C.P.; and Aziz Sheikh, M.D.
Data from Israel: Myocarditis after COVID-19 vaccines remain rare, highest risk in young males https://medicalxpress.com/news/2022-09-israel-myocarditis-covid-vaccines-rare.html
Myocarditis seven times more likely with COVID-19 than vaccines, study finds Date: October 13, 2022 Source: Penn State Summary: The risk of developing myocarditis -- or inflammation of the heart muscle -- is seven times higher with a COVID-19 infection than with the COVID-19 vaccine, according to a recent study. Patients with myocarditis can experience chest pains, shortness of breath or an irregular heartbeat. In severe cases, the inflammation can lead to heart failure and death. https://www.sciencedaily.com/releases/2022/10/221013104601.htm